title: Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.
abstract: Thrombin activatable fibrinolysis inhibitor (TAFI, or procarboxypeptidase B) is the precursor of a recently described carboxypeptidase that potently attenuates fibrinolysis. Therefore, we hypothesized that elevated plasma TAFI levels induce a hypofibrinolytic state associated with an increased risk for venous thrombosis. To evaluate this hypothesis, we developed an electroimmunoassay for TAFI antigen and used this assay to measure TAFI levels in the Leiden Thrombophilia Study, a case-control study of venous thrombosis in 474 patients with a first deep vein thrombosis and 474 age- and sex-matched control subjects. In 474 healthy control subjects, an increase of TAFI with age was observed in women but not in men. Oral contraceptive use also increased the TAFI concentration. TAFI levels above the 90th percentile of the controls (> 122 U/dL) increased the risk for thrombosis nearly 2-fold compared with TAFI levels below the 90th percentile (odds ratio, 1.7; 95% confidence interval, 1.1-2.5). Adjustment for various possible confounders did not materially affect this estimate. These results indicate that elevated TAFI levels form a mild risk factor for venous thrombosis. Such levels were found in 9% of healthy controls and in 14% of patients with a first deep vein thrombosis. Elevated TAFI levels did not enhance the thrombotic risk associated with factor V Leiden but may interact with high factor VIII levels. (Blood. 2000;95:2855-2859)
authors.affiliation: Departments of Hematology, Hemostasis and Thrombosis Research Center, Leiden University Medical Center, Leiden, The Netherlands.
authors.forename: N H
authors.initials: NH
authors.lastname: van Tilburg
authors.forename: F R
authors.initials: FR
authors.lastname: Rosendaal
authors.forename: R M
authors.initials: RM
authors.lastname: Bertina
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D000991:Antithrombins / Q000032:analysis; D015415:Biomarkers / Q000097:blood; D025901:Carboxypeptidase B2; D002268:Carboxypeptidases / Q000097:blood*; D016022:Case-Control Studies; D003276:Contraceptives, Oral; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis; D006801:Humans; D008297:Male; D008875:Middle Aged; D011486:Protein C / Q000032:analysis; D011516:Prothrombin / Q000032:analysis; D012016:Reference Values; D012044:Regression Analysis; D020246:Venous Thrombosis / Q000097:blood* / Q000453:epidemiology*
chemical_list: D000991:Antithrombins; D015415:Biomarkers; D003276:Contraceptives, Oral; D011486:Protein C; D011516:Prothrombin; D005340:Fibrinogen; D002268:Carboxypeptidases; D025901:Carboxypeptidase B2